These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8454229)

  • 1. [Effects of intravenous administration of nasaruplase, a plasminogen pro-activator, on left ventricular function and systemic hemodynamics in a canine model of acute myocardial infarction].
    Kido H; Kubo Y; Inoue S; Hayashi K; Narita Y; Uchida T; Watanabe M
    Nihon Yakurigaku Zasshi; 1993 Feb; 101(2):79-91. PubMed ID: 8454229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low incidence of hemorrhagic infarction following coronary reperfusion with nasaruplase in a canine model of acute myocardial infarction. Comparison with recombinant t-PA.
    Kido H; Hayashi K; Uchida T; Watanabe M
    Jpn Heart J; 1995 Jan; 36(1):61-79. PubMed ID: 7760515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.
    Flameng W; Vanhaecke J; Stump DC; Van de Werf F; Holmes W; Guenzler WA; Flohe L; Collen D
    J Am Coll Cardiol; 1986 Jul; 8(1):118-24. PubMed ID: 3086416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of superoxide dismutase on infarct size and postischemic recovery of myocardial contractility and metabolism in dogs.
    Vanhaecke J; Van de Werf F; Ronaszeki A; Flameng W; Lesaffre E; De Geest H
    J Am Coll Cardiol; 1991 Jul; 18(1):224-30. PubMed ID: 2050925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
    Collen D; Van de Werf F
    Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction.
    Diefenbach C; Erbel R; Pop T; Mathey D; Schofer J; Hamm C; Ostermann H; Schmitz-Hübner U; Bleifeld W; Meyer J
    Am J Cardiol; 1988 May; 61(13):966-70. PubMed ID: 2452563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infarct salvage with liposomal prostaglandin E1 administered by intravenous bolus immediately before reperfusion in a canine infarction-reperfusion model.
    Smalling RW; Feld S; Ramanna N; Amirian J; Felli P; Vaughn WK; Swenson C; Janoff A
    Circulation; 1995 Aug; 92(4):935-43. PubMed ID: 7641377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary thrombolysis with intravenous urokinase in patients with acute myocardial infarction.
    Mathey DG; Schofer J; Sheehan FH
    Am J Med; 1987 Aug; 83(2A):26-30. PubMed ID: 3631114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
    Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary reperfusion studies with pro-urokinase in acute myocardial infarction: evidence for synergism of low dose urokinase.
    Kasper W; Hohnloser SH; Engler H; Meinertz T; Wilkens J; Roth E; Lang K; Limbourg P; Just H
    J Am Coll Cardiol; 1990 Sep; 16(3):733-8. PubMed ID: 2117622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant tissue-type plasminogen activator ameliorates ischemic derangements induced by thrombotic occlusion in closed chest anesthetized dogs.
    Egashira K; Kawai K; Nagano M; Sakuma A; Nakamura M; Tomoike H
    J Am Coll Cardiol; 1992 Jul; 20(1):218-25. PubMed ID: 1607528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving concepts in the treatment of acute myocardial infarction.
    Lange RA; Hillis LD
    Am J Med Sci; 1988 Aug; 296(2):143-52. PubMed ID: 3041833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction.
    Van de Werf F; Nobuhara M; Collen D
    Ann Intern Med; 1986 Mar; 104(3):345-8. PubMed ID: 3080936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue-type plasminogen activator therapy versus primary coronary angioplasty: impact on myocardial tissue perfusion and regional function 1 month after uncomplicated myocardial infarction.
    Agati L; Voci P; Hickle P; Vizza DC; Autore C; Fedele F; Feinstein SB; Dagianti A
    J Am Coll Cardiol; 1998 Feb; 31(2):338-43. PubMed ID: 9462577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additional myocardial salvage by coadministration of the epoprostenol analog taprostene to recombinant single-chain urokinase-type plasminogen activator in a canine coronary thrombosis model.
    Groves R; Schneider J; Friderichs E; Giertz H; Flohé L
    Arzneimittelforschung; 1989 Apr; 39(4):534-8. PubMed ID: 2665759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolytic therapy reduces the incidence of left ventricular thrombus after anterior myocardial infarction. Relationship to vessel patency and infarct size.
    Pizzetti G; Belotti G; Margonato A; Carlino M; Gerosa S; Carandente O; Chierchia SL
    Eur Heart J; 1996 Mar; 17(3):421-8. PubMed ID: 8737217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Detection of early reperfusion and prediction of left ventricular damage from the course of increased ST values in acute myocardial infarct with thrombolysis].
    Dissmann R; Goerke M; von Ameln H; Rennhak U; Schroeder J; Linderer T; Schröder R
    Z Kardiol; 1993 May; 82(5):271-8. PubMed ID: 8328176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of intravenous thrombolytic therapy with pro-urokinase in acute myocardial infarction.
    Bode C; Schuler G; Schwarz F; Zimmermann R; Horn A; Kuebler W
    Am J Cardiol; 1987 Aug; 60(4):371. PubMed ID: 3113225
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced myocardial salvage by combined treatment with recombinant single-chain urokinase-type plasminogen activator and recombinant human superoxide dismutase in a canine coronary thrombosis model.
    Fincke U; Schneider J; Friderichs E; Giertz H; Flohé L
    Arzneimittelforschung; 1988 Jan; 38(1):138-42. PubMed ID: 3365272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.